Investor Zoom Webinar
11am AEDT Friday 20 January (tomorrow)
You are invited to register via this link:
https://us06web.zoom.us/webinar/register/WN_W7xneWCOTkuPF16AW1sbvQ
Questions may be tabled as you register or during the webinar

BIO-GENE AND STK BIO-AG TECHNOLOGIES AGREE BINDING TERMS ON A GLOBAL COLLABORATION TO DEVELOP, REGISTER AND COMMERCIALISE QCIDE™ FOR CROP PROTECTION APPLICATIONS

Bio-Gene and STK sign a binding term sheet covering the following commercial terms:

- **Bio-Gene grants STK a world-wide non-exclusive licence to develop Qcide™ technology for crop protection applications, as well as aquaculture, and professional turf and ornamentals markets**
- **STK funds all costs associated with securing the Active Ingredient registration for Qcide**
- **Bio-Gene to have full access to Active Ingredient registrations to support other commercial opportunities in crop and non-crop applications**
- **Both companies to evaluate the opportunity for Bio-Gene to act as sales agent for STK products in Australia & New Zealand**
- **Up to 90-days to finalise transaction documents**

Bio-Gene Technology Limited (ASX: BGT, 'Bio-Gene' or 'the 'Company'), an agtech development company enabling the next generation of novel insecticides, and STK Bio-Ag Technologies (STK), an Israeli based developer and marketer of botanical and 'hybrid' crop protection solutions, announced today that binding terms have been agreed on a global collaboration partnership for the commercialisation of Bio-Gene's Qcide product in crop protection and other market segments. Bio-Gene and STK have allowed up to 90-days to complete the transaction documentation. As the Term Sheet is binding and the collaboration is in place, the transaction documents will incorporate the customary indemnities and warranties together with the finalisation of the development plan. All other terms and conditions in the Term Sheet will be replicated in the final documents. The collaboration will continue while at least the USA EPA registration remains in place (reviewed by the EPA at least every 15 years from registration) or is terminated for lack of performance by either party. In the unlikely event that the transaction documents are not completed, the collaboration will continue on the basis of the terms outlined in the Term Sheet.

STK applies advanced botanical science and bio-ag technology in the development and commercialisation of botanical crop protection solutions for growers worldwide and has operations and product registrations in more than 30 countries.

Bio-Gene and STK entered into a confidential Material Transfer Agreement in 2021 that facilitated STK's internal assessment of Qcide technology across a range of potential applications. Those studies mainly focused on crop protection applications but are also relevant for professional turf and ornamental markets and could be extrapolated into aquaculture, where STK's Aqua Division operates.

Commenting on the execution of the term sheet, Bio-Gene CEO, Richard Jagger said: "STK has been working intensively with our technology for some time now, and the data they have obtained give both companies great confidence in the applicability for STK's target markets. Not only does STK see the commercial potential for our

technology, but they see the benefit in collaborating with Bio-Gene to accelerate the registration process; to invest in an additional production base; and to explore mutually beneficial marketing arrangements."

Under the proposed agreement, STK intends to fully fund registration costs relating to the Qcide Active Ingredient. This will include required efficacy and toxicology studies, field trials, the generation of manufacturing data and preparation of the regulatory submission. While STK would have ownership of the resulting registration, Bio-Gene will continue to own the IP relating to Qcide. Bio-Gene has unlimited access to the registration and can work with other commercial partners to develop and commercialise products in all market segments, including those licenced to STK on a non-exclusive basis.

The proposed collaboration will also see STK utilise its existing expertise and capabilities in plantations and extraction technology to develop a secondary manufacturing and supply source for Qcide.

Both companies have agreed to assess the potential for Bio-Gene to be appointed as a marketing and sales agent for STK products (products based on Qcide and other STK products) in Australia and New Zealand.

This is a significant transaction for Bio-Gene as it provides for the global co-development of Qcide which incorporates:

- a major financial investment that commits STK to fully fund studies to achieve global registrations of Qcide;
- access to the demonstrated expertise of one of the leading developers of botanical based crop protection solutions;
- further capability in developing manufacturing solutions for botanical based products; and
- global access for Bio-Gene in all market segments.

Mr Jagger further commented: "This is a very strong validation of the potential for our Qcide technology. STK is an established global developer and provider of innovative, environmentally friendly botanical solutions in the crop protection and aquaculture segments. STK's commitment and confidence is reflected in a multi-million dollar investment in registration activity and manufacturing capacity."

Shay Shaanan, Executive Vice President, R&D and Business Development for STK commented: "STK is very excited about this collaboration with Bio-Gene. Our research to date suggests there are great applications for the technology, which fall into our areas of expertise. Throughout the evaluation phase, we have developed a strong relationship with Bio-Gene, which will serve all of us well as we work together to develop new products for the market."

The crop protection market is the largest market segment for insecticides globally. While it is highly fragmented and specialised, it is valued at around US$16.6 billion per annum and growing[1].

The focus on naturally derived products continues to be a priority for much of the agricultural and public health industries, and the identification of a new Mode of Action is a key value proposition for Bio-Gene's commercial partners and their customers. Insecticide markets around the world are currently facing pressures of resistance to incumbent products, and public safety concerns over the use of various chemistries in controlling pest populations.

The introduction of products with a novel Mode of Action, such as Flavocide™ and Qcide, is critical for pest management to address populations resistant to currently used chemistry and reduce the potential of increased insecticide resistance in the future. Products of natural origin are seen as favourable alternatives to many existing products which is a key consideration for companies developing new insecticide solutions.

Bio-Gene's CEO Richard Jagger will lead a briefing webinar at 11am AEDT Friday, 20 January 2023 to provide investors with a detailed overview of the arrangements with STK, the benefits of this arrangement to Bio-Gene and a general update.

To attend the presentation, please register using the following link:
https://us06web.zoom.us/webinar/register/WN_W7xneWCOTkuPF16AW1sbvQ

The presentation slides will be available on the company website shortly before the event is scheduled to commence.

Approved for release by the Board of Directors.

ENDS

For further information, please contact:

Bio-Gene Technology Limited:
Richard Jagger
Chief Executive Officer
P: 03 9068 1062
E: bgt.info@bio-gene.com.au

Roger McPherson
CFO & Company Secretary
P: 03 9068 1062
E: bgt.info@bio-gene.com.au

IR/Media
Rudi Michelson
Monsoon Communications
P: 03 9620 3333
E: rudim@monsoon.com.au

About Bio-Gene Technology Ltd

Bio-Gene is an Australian agtech company enabling the next generation of novel insecticides to address the global problems of insecticide resistance and toxicity. Bio-Gene's novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones.

Beta-triketone compounds have demonstrated insecticidal activity (e.g. kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide manufacturers in applications across crop protection and storage, public health, consumer applications and animal health. The Company's aim is to develop and commercialise a broad portfolio of targeted insect control and management solutions.

About STK Bio-AG Technologies

Founded in 1994, STK is a bio-ag technology company, committed to protecting crops while meeting the highest sustainability standards. Our breakthrough, botanical crop protection solutions – a synergy of cutting-edge scientific research and technology – enhance the safety, yield and quality of multiple crops. STK helps growers to deliver cleaner and healthier products to market. Our organic and hybrid protection solutions are easily integrated into conventional spraying programs, helping to advance the IPM (Integrated Pest Management) approach. They enable everyone to adhere to regulatory standards and support the transition to sustainable agriculture.

STK Bio-AG Technologies empowers growers around the globe with botanical crop solutions that meet the challenges of plant protection and sustainable agriculture in the 21st century.

Qcide™ and **Flavocide™** are trademarks of Bio-Gene Technology Limited.

[1] *Fortune business insights, 2021: Crop protection chemicals market size… 2021-2028.*